- Furthers Baxter’s continued innovation in medication delivery and management
- Integrates Baxter’s decades of leadership in infusion therapy with innovative digital health solutions to build on the company’s proven technology for helping to protect infusions from medication errors
- Supports neonatal and pediatric clinicians and anesthesiologists to help provide safe, accurate infusions for vulnerable patients
Ascendis Pharma Announces Resubmission Of TransCon PTH NDA For Adults With Hypoparathyroidism Expected Before Mid-November 2023
Ascendis Pharma A/S (NASDAQ:ASND) today announced it will report third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, after the close of the U.S. financial markets. In
